NICE TA563 - with aromatase inhibitor for previously untreated hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer. (Decision date - March 2019)
NICE TA579 - with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine therapy. (Decision date - June 2019)
NICE TA725 - Abemaciclib with fulvestrant for treating hormone
receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. This guidance updates
and replaces NICE TA579 (Decision date - Oct 2021)
NICE TA810 - Abemaciclib with endocrine therapy for adjuvant treatment
of hormone receptor-positive, HER2-negative, node-positive early breast cancer
at high risk of recurrence (Decision date - August 2022)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions